Medicine | Oncology
Prostate cancer
Treatment
Photodynamic therapy


Home > Disciplines > Medicine > Oncology > Prostate cancer > Treatment > Photodynamic therapy



Contents



Overview
Laboratory Investigations
Clinical investigations
Newly diagnosed tumors
Recurrent tumors
Miscellanea



Overview



Wang L, Yang H, Li B.
Photodynamic therapy for prostate cancer: a systematic review and meta-analysis.
Prostate Int. 2019 Sep;7(3):83-90. doi: 10.1016/j.prnil.2018.12.002. Epub 2018 Dec 27.
Source . Similar articles



Laboratory investigations




Clinical investigations


.

Azzouzi AR, Vincendeau S, Barret E, Cicco A, Kleinclauss F, van der Poel HG, Stief CG, Rassweiler J, Salomon G, Solsona E, Alcaraz A, Tammela TT, Rosario DJ, Gomez-Veiga F, Ahlgren G, Benzaghou F, Gaillac B, Amzal B, Debruyne FM, Fromont G, Gratzke C, Emberton M; PCM301 Study Group.
Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial.
Lancet Oncol. 2017 Feb;18(2):181-191. doi: 10.1016/S1470-2045(16)30661-1. Epub 2016 Dec 19.
Source | Full text | Similar articles



.

Freedland SJ.
Low-risk prostate cancer: to treat or not to treat.
Lancet Oncol. 2016 Dec 19. pii: S1470-2045(16)30651-9. doi: 10.1016/S1470-2045(16)30651-9. [Epub ahead of print]
Source | Full text | Similar articles
Comment on:
Azzouzi AR et al., Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial.
Lancet Oncol. 2017 Feb;18(2):181-191. doi: 10.1016/S1470-2045(16)30661-1. Epub 2016 Dec 19.
Source / Full text



.

Taneja SS.
Re: Padeliporfin Vascular-Targeted Photodynamic Therapy versus Active Surveillance in Men with Low-Risk Prostate Cancer (CLIN1001 PCM301): An Open-Label, Phase 3, Randomised Controlled Trial.
J Urol. 2017 Aug;198(2):255-257. doi: 10.1016/j.juro.2017.05.029. Epub 2017 May 10.
Source | Full text | Similar articles
Comment on:
Azzouzi AR et al., Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial.
Lancet Oncol. 2017 Feb;18(2):181-191. doi: 10.1016/S1470-2045(16)30661-1. Epub 2016 Dec 19.
Source / Full text



Newly diagnosed tumors




Recurrent tumors




Miscellanea